MCMedicalCodingSoftware
Free trial
XW023V7

XW023V7 — Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7

Billable / specific codeICD-10-PCS

CMS abbreviated title: Introduce COVID19 Vacc Ds 3 in Muscle, Perc, New Tech 7

How XW023V7 is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology — What family of procedure this is
  2. WBody systemWhich system it acts on
  3. 0Root operationThe objective — the verb of the procedure
  4. 2Body partThe specific site
  5. 3ApproachHow the site was reached
  6. VDeviceWhat was left in place, if anything
  7. 7QualifierA further distinction where one applies

Codes near XW023V7

In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.

  • XW013V7Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW013W5Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
  • XW013W7Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
  • XW01X27Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7
  • XW020D8Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8
  • XW023S6Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023T6Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023U6Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023V7Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7
  • XW023W7Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7
  • XW023X7Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
  • XW023Y7Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
  • XW03308Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0333AIntroduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW0334AIntroduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW03357Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03358Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8
ICD-10-PCSFY2026